Abstracts tagged "Immunoglobulin (IG)"

Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Simon Bowman¹, Robert Fox ², Thomas Dörner ³, Xavier Mariette ⁴, Athena Papas ⁵, Thomas Grader-Beck ⁶, Benjamin A. Fisher ⁷, Filipe Barcelos ⁸, Salvatore De Vita ⁹, Hendrik Schulze-Koops ¹⁰, Robert J. Moots ¹¹, Guido Junge ¹², Janice Woznicki ¹³, Monika Sopala ¹², Wen-Lin Luo ¹³ and Wolfgang Hueber ¹², ¹University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ²Scripps Memorial Hospital and Research Institute, La Jolla, California, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Tufts School of Dental Medicine, Massachusetts, ⁶Johns Hopkins University, Baltimore, ⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, ⁸Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, ⁹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ¹⁰Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ¹¹Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ¹²Novartis Pharma AG, basel, Switzerland, ¹³Novartis Pharmaceuticals Corporation, New Jersey
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
Abstract Number: 845 • 2019 ACR/ARP Annual Meeting
Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions
Stefanie Wade¹ and Vasileios Kyttaris ¹, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Rituximab (RTX) is used in a wide variety of rheumatic disease. Emerging guidelines suggest measuring immunoglobulins (Ig) at pre-treatment screening and prior to repeat…
Abstract Number: 973 • 2019 ACR/ARP Annual Meeting
Serum IgG4 Concentrations Differ According to Race and Sex
Tyler Harkness¹, Xiaoqing Fu ¹, Yuqing Zhang ², Hyon K. Choi ², John Stone ³, Kimberly Blumenthal ¹ and Zachary Wallace ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Elevated IgG4 concentrations are used to support a diagnosis of IgG4-related disease (IgG4-RD). IgG4 concentrations are reported to be higher in male IgG4-RD patients…
Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting
Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
Thomas Huizinga¹, René Toes ¹, Michael Weinblatt ², Michael Schiff ³, Roy Fleischmann ⁴, Yedid Elbez ⁵, Sean Connolly ⁶, Michael Maldonado ⁶ and Sheng Gao ⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ³University of Colorado, Denver, CO, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Excelya, Boulogne-Billancourt, France, ⁶Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: 832 • 2018 ACR/ARHP Annual Meeting
Immunoglobuline a Vasculitis: Comparison between Pediatric and Adult Population
Martin Brom¹, Ignacio Javier Gandino², Marina Scolnik³, Valeria Scaglioni³, Maria Britos⁴, Carmen De Cunto⁴ and Enrique R Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ⁴Pediatric Rheumatology, Hospital Italiano De Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Immunoglobuline A (IgA) Vasculitis, formerly known as Henoch-Schönlein purpura, is a small-vessel leukocytoclastic vasculitis due to deposition of IgA1, a subclass of IgA. Although…
Abstract Number: 2051 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Jing Jing Wang¹, William Murray-Brown², Alexander Colella¹, Malcolm D. Smith³, Tim Chataway⁴, Jenny Walker², William H. Robinson⁵, Mihir D Wechalekar² and Tom Gordon^1,6, ¹Immunology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders University, Adelaide, Australia, ³Rheumotology, Flinders University, Adelaide, Australia, ⁴Proteomic Facility, Flinders University, Adelaide, Australia, ⁵Stanford University, Palo Alto, CA, ⁶Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Rheumatoid factors (RFs) are associated with disease activity and joint damage in rheumatoid arthritis (RA) and thought to play a pathogenic role in disease.…
Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Emanuele Calabresi¹, Simone Barsotti², Elisa Cioffi³, Alessandra Tripoli¹, Andrea Delle Sedie¹, Laura Bazzichi⁴, Ornella Mazzarella¹, Rossella Neri⁴ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…
Abstract Number: 236 • 2018 ACR/ARHP Annual Meeting
Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab
Joana Caetano¹, Frederico Batista¹ and Jose Delgado Alves^2,3, ¹Department of Medicine IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal, ²CEDOC/NOVA Medical School, Lisbon, Portugal, ³Department of Medicina IV, Systemic Immunomediated Diseases Unit, Fernando Fonseca Hospital, Amadora, Portugal
Background/Purpose: Rituximab (RTX) is an effective immunosuppressive therapy for many autoimmune diseases. Secondary hypogammaglobulinemia (hypoIg) can occur mainly after repeated cycles of RTX. The risk…
Abstract Number: 773 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Immunoglobulins Level and Infection Risk in Adult Patients with Systemic Lupus Erythematosus
Ibrahim Almaghlouth^1,2, Jiandong Su³, Eleanor Pullenayegum⁴, Sindhu Johnson⁵, Dafna D Gladman³ and Murray Urowitz⁶, ¹Division of Rheumatology, Department of medicine, King Saud University, King Khalid University Hospital, Riyadh, Saudi Arabia, ²Division of Rheumatology, Department of medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Infection is a major cause of mortality in all stages of disease in systemic lupus erythematosus (SLE). Several risk factors for infection have been…
Abstract Number: 2166 • 2017 ACR/ARHP Annual Meeting
Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
Simone Barsotti^1,2, Ilaria Cavazzana³, Rossella Neri⁴, Francesco Locatelli⁵, Mara Taraborelli^3,6, Elisa Cioffi⁷, Ilaria Chiapparoli⁵, Angela Tincani⁸, Franco Franceschini³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foudation, Pavia, Italy, ⁶Internal Medicine; Ospedale Mellini, Chiari (Brescia), Italy, ⁷Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁸Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Despite the absence of specific guidelines or trials on intravenous immunoglobulins (IvIg) in patients with idiopathic inflammatory myopathies (IIM), the treatment is considered effective…
Abstract Number: 2719 • 2017 ACR/ARHP Annual Meeting
Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?
Tadeja Kuret¹, Katja Lakota^1,2, Polona Žigon¹, Manca Ogrič¹, Boris Lestan¹, Snezna Sodin Semrl^1,2, Saša Čučnik^1,3, Matija Tomšič^1,4 and Alojzija Hočevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia, ³Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, ⁴University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Background/Purpose: Immunoglobulin A vasculitis (IgAV, formerly Henoch–Schönlein purpura) is a small vessel, immune complex vasculitis characterized by dominant IgA deposits in the vascular wall. Clinical…
Abstract Number: 62 • 2016 ACR/ARHP Annual Meeting
Increased Frequency of Anti-Drug Antibodies in Patients Carrying Compatible IgG1 Allotypes and Treated with Anti-TNF Antibodies
Antonio Gonzalez¹, Rosario Lopez-Rodriguez¹, Ana Martinez², Chamaida Plasencia-Rodriguez², Andrea Jochems², Dora Pascual-Salcedo² and Alejandro Balsa², ¹Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain
Background/Purpose: One of the causes of insufficient response to biological drugs is the production of anti-drug antibodies (ADA) (1). These antibodies can decrease the effectiveness…
Abstract Number: 958 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Philip J Mease¹, Mark C. Genovese², Michael Weinblatt³, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Heikki T. Mansikka⁴, Amit Khatri⁴, Ahmed A. Othman⁴, Neil Wishart⁴, John Liu⁴ and Robert J. Padley⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Stanford University Medical Center, Palo Alto, CA, ³Brigham and Women’s Hospital, Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].